--------------------------------------------------------------------------------
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
--------------------------------------------------------------------------------
                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

                        Date of Report: October 11, 2007
                        (Date of earliest event reported)
--------------------------------------------------------------------------------

                                  ABIOMED, Inc.
             (Exact name of registrant as specified in its charter)


                   Delaware                                  04-2743260
(State or other Jurisdiction of Incorporation)      (IRS Employer Identification
                                                             Number)

                                     0-20584
                            (Commission File Number)

                              22 Cherry Hill Drive
                                Danvers, MA 01923
          (Address of Principal Executive Offices, including Zip Code)

                                 (978) 646-1400
              (Registrant's Telephone Number, including Area Code)

                                 Not Applicable
          (Former Name or Former Address, if Changed Since Last Report)
--------------------------------------------------------------------------------

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

|_| Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))
--------------------------------------------------------------------------------



--------------------------------------------------------------------------------

Item 8.01 Other Events.

     On October 11, 2007 we issued a press release announcing an update on the
510k clearance process for our Impella 2.5 product. A copy of the press release
is set forth as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01   Financial Statements and Exhibits.

      (d) Exhibits

Number       Title
--------     -------------------------------------------------------------------
99.1         Press Release dated October 11, 2007.



--------------------------------------------------------------------------------
                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

               ABIOMED, Inc.

               By:  /s/ Daniel J. Sutherby
                    --------------------------------------
                       Daniel J. Sutherby
                       Chief Financial Officer

Date: October 11, 2007